Literature DB >> 2681604

Angiotensin converting enzyme inhibitors and renal function.

A Mimran1, J Ribstein.   

Abstract

Angiotensin converting enzyme (ACE) inhibitors are useful in the treatment of hypertension. However, acute renal deterioration may occur in some conditions where angiotensin plays a crucial role in the regulation of the glomerular filtration rate (GFR), such as volume depletion, severe stenosis of both renal arteries and stenosis of the renal artery of a single functioning kidney. Acute renal failure induced by ACE inhibition may develop without a reduction in systemic blood pressure it is enhanced by prior sodium depletion and is reversible when treatment is withdrawn. The relative superiority of ACE inhibitors in slowing the progression of chronic parenchymal renal disease remains to be demonstrated, although promising results have been reported in patients with diabetic nephropathy.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2681604

Source DB:  PubMed          Journal:  J Hypertens Suppl        ISSN: 0952-1178


  4 in total

Review 1.  Influence of antihypertensive therapy on renal function.

Authors:  U Frei; R Schindler; K M Koch
Journal:  Clin Investig       Date:  1992

2.  Effects of ACE inhibition on renal haemodynamics in essential hypertension and hypertension associated with chronic renal failure.

Authors:  R A Sánchez; C A Traballi; E J Marcó; B H Gilbert; A J Ramírez; G Long
Journal:  Drugs       Date:  1991       Impact factor: 9.546

3.  Regression of left ventricular hypertrophy and improvement of renal hemodynamics in hypertensive patients treated with quinapril.

Authors:  L De Caprio; M L De Rosa; A Di Palma; C Lirato; P Caccese; M Sestito; S Lastoria; A M Cicatiello; F Rengo
Journal:  Cardiovasc Drugs Ther       Date:  1994-10       Impact factor: 3.727

4.  The protective effects of liguzinediol on congestive heart failure induced by myocardial infarction and its relative mechanism.

Authors:  Qi Chen; Dini Zhang; Yunhui Bi; Weiwei Zhang; Yuhan Zhang; Qinghai Meng; Yu Li; Huimin Bian
Journal:  Chin Med       Date:  2020-06-15       Impact factor: 5.455

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.